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A novel point mutation resulting in a glutamate-to-glycine substitution in PRNP at codon 200, E200G with codon
129 MV polymorphism (cis valine) and type 2 PrPSc was identified in a patient with a prolonged disease course
leading to pathology-proven Jakob-Creutzfeldt disease. Despite the same codon as the most common genetic form
of human PRNP mutation, E200K, this novel mutation (E200G) presented with a different clinical and pathological
phenotype, including prolonged duration, large vacuoles, no vacuolation in the hippocampus, severe neuronal loss
in the thalamus, mild cerebellar involvement, and abundant punctate linear and curvilinear deposition of PrPSc in
synaptic boutons and axonal terminals along the dendrites.
Keywords: Creutzfeldt-Jakob disease, E200K, familial CJD, Synaptic PrPSc, Curvilinear PrPScBackground
Human prion diseases are unique in medicine as they
occur as spontaneous, genetic and acquired forms. Sporadic
Jakob-Creutzfeldt disease (sCJD) is the most common
human prion disease, accounting for approximately 85-90%
of cases, whereas autosomal dominant genetic forms, due to
more than 30 mutations in the prion protein gene (PRNP),
account for 10-15% of cases [1]. Glu200Lys (E200K) and
Asp178Asn (D178N) are the most common PRNP mu-
tations worldwide [2-8]. At least four founder groups of
E200K are known with the two largest populations in the
Middle East (Libyan Jews) and Slovakia [4,5,8-10]. We
report a novel point mutation of PRNP at codon 200
resulting in a glutamate-to-glycine substitution, E200G,
in a pathology-proven patient of British descent and
compare findings to those of E200K cases.Case presentation
A 59-year-old Caucasian woman with a reported 25-month
history of motor and cognitive problems was referred to* Correspondence: mgeschwind@memory.ucsf.edu
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stated.our clinical research center with suspected sCJD. Her first
obvious symptoms began 25 months prior (“onset”) with
gradual onset of gait imbalance, fatigue and “loss of mental
acuity,” although there might have been very subtle changes
in personality (irritability, decreased understanding and
appreciation of humor, poor planning) even five months
earlier. One month after onset, she developed difficulty
walking. By four months, she could no longer correctly
balance her checkbook and had worsened handwriting.
At six months, language difficulties began, particularly
noticeable during phone conversations. At seven months,
she began missing freeway exits (reasons unclear). At
12 months, she developed a head tremor and at 17 months,
nighttime leg cramps. By 18 months, all of the above symp-
toms had worsened, and she required a cane. At 20 months,
she still was doing some, albeit more limited, driving, shop-
ping, and light housework, with some fluctuation of her gait
and memory abilities. By 22 months, she could no longer
do these activities. At 25 months, when she first visited our
center, she was wheelchair bound and had difficulty follow-
ing conversations.
Her past medical history was unremarkable. Her father
died at 50 from alcoholism and pneumonia, with presumed
“alcohol-related dementia,” which progressed rapidly dur-
ing the last three months and “fast movements” during his. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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11 years younger, and a half-sibling whose status is un-
known (Figure 1).
At 25 months, she was alert and partially oriented,
fluent, slightly hypophonic, but not dysarthric. She had
mild anomia. Her MMSE was 26/30, missing points for
floor, county and recall. More extensive neuropsychological
testing revealed mild cognitive impairment across multiple
domains, including visual memory and executive function
(Table 1). Examination also was remarkable for jerky ocular
pursuit (horizontal and vertical), increased latency with
mild decreased velocity of horizontal saccades, extrapyram-
idal features (resting tremor in the face and bilateral upper
extremities, action tremor in the bilateral upper extremities,
mild cogwheel rigidity in the bilateral upper extremities,
and bradykinesia greatest in the right arm and left leg),
symmetric, distal, length-dependent, decreased pinprickFigure 1 Family pedigree. Family pedigree of the proband of British desc
indicate males. Those whose gender is not disclosed are indicated with rho
numerals “3” and “5” indicate the numbers of individuals. The proband with
arrowhead and her sibling with the same E200 mutation is also marked by
CHF = congestive heart failure, h/o RPD = history of rapidly progressive demand temperature in legs, asymmetric lower extremity
reflexes (left side brisker), and cerebellar dysfunction
(wide-based gait requiring assistance and truncal ataxia).
There was no limb ataxia, myoclonus, dystonia, chorea,
alien limb, or higher cortical sensory signs.
Her initial brain MRI at 17 months showed subtle
cortical ribboning and striatal hyperintensity on FLAIR
and DWI with restricted diffusion on ADC, which were
more distinct and extensive by 25 months (Figure 2a-f ).
Her first EEG, at 25 months, showed bilateral slowing,
predominant in the frontal and posterior regions, but
no triphasic or epileptiform discharges. Extensive blood
tests to rule out conditions other than CJD were nega-
tive. Basic CSF findings at 25 months were normal
(RBC 1, WBC 1, protein 37, glucose 75, no oligoclonal
bands, and IgG index of 0.5), except she had an elevated
total tau of 1351 pg/mL (“>1150 pg/ml consistent withent with E200G mutation. Circles indicate females, and squares
mbi. A diagonal bar in the symbols indicate deceased. Arabic
the E200G mutation (E200G+) is indicated by closed circle and
“E200G+” (+EtOH = alcoholism, d. = died at age, lung ca = lung cancer,
entia).
Table 1 Serial longitudinal neuropsychological assessment of E200G case
Visit 1 Visit 2 Visit 3
25 months 26 months 28 months
Raw (Z-score) Raw (Z-score) Raw (Z-score)
Global cognition
MMSE 261 242 16
Memory
CVLT trial 5 4 (−4.00) 4 (−4.00) 0 (−5.00)
CVLT delay 1 (−4.00) 1 (−4.00) 0 (−4.00)
CVLT recog hits 15 (0.00) 15 (0.00) 13 (−1.00)
CVLT recog false pos 3 (−0.50) 3 (−0.50) 16 (−4.00)
Benson figure delay recall 3 (−4.17) 0 (−5.48) N/D
Mean memory Z-score −2.53 −2.80 −3.50
Executive function
Modified trails 59" (−3.00) 119" (−8.62) 120" (−8.71)
Design fluency N/A 5 (−2.28) 0 (−4.07)
Digit backwards span 3 (−1.85) 3 (−1.85) 3 (−1.85)
Stroop inhibition 31 (−2.25) 19 (−3.50) N/D
Mean executive Z-score −2.37 −4.06 −4.88
Language
BNT-Abbrev 13 (−1.66) 15 (+0.55) N/D
Visuospatial
Benson figure copy 13 (−1.27) 14 (−1.36) N/D
1 Missed 2 points for orientation and 2 on recall. 2 Missed 3 points for orientation and 3 on recall. Abbreviations and Definitions: MMSE Mini-Mental State Examination,
CVLT California Verbal Learning Test-II (16 word list), Recog Recognition, False Pos False Positive Total, Modified Trails Abbreviated trail-making task using
numbers and days of the week, BNT-Abbrev Abbreviated (15-item) Boston Naming Test, N/D patient unable to perform, N/A not administered.
Figure 2 Serial brain MRIs, classic for CJD. Brain MRIs at 17 (a-c), 25 (d-f), and 28 (g-i) months. Solid arrows indicate cortical ribboning. Dotted
arrows indicate deep nuclei hyperintensity. (a) Initial brain MRI was read by us as “ambiguous” for CJD, but was felt to show mild frontal-parietal atrophy
and punctate subcortical white matter hyperintensities on FLAIR (b) DWI shows subtle cortical ribboning in the anterior and median cingulate and right
posterior cingulate and subtle striatal hyperintensity. (c) ADC map shows hypointensities in the same regions as on DWI. (d) FLAIR (axial) brain MRI at
25 months reveals moderate diffuse cortical atrophy. (e) DWI now shows cortical ribboning in the right frontal cortex, and anterior and median cingulate,
and hyperintensities in bilateral caudate and putamen with anterior to posterior gradient. (f) ADC map shows hypointensities in the areas of DWI
hyperintensity. (g) FLAIR MRI at 28 months shows more prominent cingulate cortical ribboning hyperintensity in the striatum. (h) Cortical ribboning is more
prominent than three months prior. (i) ADC map shows hypointensities consistent with restricted diffusion.
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and mildly elevated (“intermediate”) neuron-specific
enolase of 27 ng/mL (Mayo Laboratories; normal < 15,
intermediate 15–35, >35 ng/ml consistent with CJD).
Follow-up neuropsychological testing one and three
months later (at 26 and 28 months) showed further de-
terioration in memory and executive function (Table 1).
Her brain MRI at 28 months showed profound cortical
atrophy, brighter and more extensive DWI hyperintensi-
ties with increased restricted diffusion in these regions
(Figure 2g-i). She passed away at 30 months, 5 months
after diagnosis. Direct sequencing of the PRNP gene
open reading frame, and subsequent cloning experiments
(NPDPSC), from blood (and later from frozen brain tissue)
revealed an E200G mutation with heterozygosity at codon
129 (MV; cis valine) in PRNP. Her younger asymptom-
atic full sibling carried the same mutation and codon
129 polymorphism.
Autopsy was performed one day after her passing. The
brain weighed 1175 gm (normal 1100–1400 gm). Gross
brain pathology showed atrophy in the frontal lobe, right
greater than left, and loss of pigmented neurons in the
substantia nigra. Microscopic examination revealed PrPSc
deposition characteristic of CJD, with both perivacuolar
and diffuse finely granular synaptic staining in the cerebral
cortex (Figure 3a). Most PrPSc consisted of finely granular
deposits (2–4 μm diameter), which were distributed around
and, occasionally, inside the neuronal perikarya and pro-
cesses (Figure 3c). Occasional larger plaque-like deposits
were also seen (30–40 μm) (Figure 3a). In addition there
were abundant punctate, linear and curvilinear arrays of
PrPSc in the striatum (Figures 3d and 4) and other regions
including Ammon’s horn of the hippocampus, substantia
nigra, midbrain tegmentum, periaqueductal gray, and
medullary inferior olivary nucleus (Figure 4). MAP-2
immunostaining showed the linear and curvilinear arrays
were associated with dendrites (Figure 3i). PrPSc was not
co-localized with axonal markers including neurofilament
H and phospho-neurofilament H (not shown). Some of the
unusual linear and curvilinear PrPSc deposits co-localized
with or were adjacent to synaptophysin (presynaptic vesicle
membrane protein) immunostaining, demonstrating the
presence of PrPSc in synaptic boutons and probably also
in pre-synaptic axonal terminals (Figure 3j).
In most regions of the cortex, vacuolation was in layers
II-VI, more severely affecting layers III-VI (not shown),
but in the insular cortex, it was confined to layers V
and VI (Figure 3b). The mean diameter of gray matter
vacuoles was 14.9 μm (range 4–108 μm), significantly
larger than those observed in the NPDPSC E200K-129V
(mean: 11.9 μm, range: 4–72 μm; P < 0.016) and E200K-
129M (mean: 11.8 μm, range: 4–69 μm; P < 0.016) cohorts.
Vacuole size between the E200K-129V and -129M
NPDPSC cohorts was not significantly different (P > 0.016).Reactive astrocytosis co-localized with vacuolation and
PrPSc deposition in all cortical regions and striatum,
except in the insular cortex, where it was most intense
in layers I-IV that contained sparse vacuolation and
minimal PrPSc (not shown).
The hippocampus did not exhibit vacuolation, or
neuronal loss despite mild to severe PrPSc deposits; fur-
thermore astrocytosis was absent or moderately reactive
(Figure 3e, f, Table 2). The thalamus showed overall mild
vacuolation and mild to severe PrPSc deposits, severe
neuronal loss, and severe reactive astrocytosis, especially
in the medial nuclei (Figure 3g, Table 2); in contrast, the
thalami of the NPDPSC E200K-129M and -129V cases
showed vacuoles but neither neuronal loss nor astrocyto-
sis (Figure 3h). All brain regions were affected to a moder-
ate or severe extent, except the cerebellum, which only
had sparse PrPSc staining, no vacuolation, and mild react-
ive astrocytosis in the cortex (not shown). In the cerebellar
molecular layer, there were loose, round aggregates of
fine granules, which occasionally were around cell bodies
(not shown). Plaque-like PrPSc deposits were observed
in the granular cell layer, whereas perineuronal and
intraneuronal staining patterns were predominant in the
dentate nucleus, which also showed a moderate number of
linear and curvilinear arrays (Figures 3c and 4). Table 2
shows lesion profiles of the E200G case.
Because other neurodegenerative proteins occasionally
are found in sCJD and gPrD [11-15], we examined the
status of hyperphosphorylated tau (Hτ), β-amyloid (Aβ),
α-synuclein, TPD 43, and ubiquitin in our patient. The
CP13 antibody specific for Hτ was used to stain sections
from the insula and putamen, the hippocampus and en-
torhinal cortex (EC), the inferior temporal lobe, and the
midbrain with substantia nigra. Hτ was found exclu-
sively and focally in layers 3 and 4 of the EC (Figure 5a).
Application of the 4G8 antibody for abnormal Aβ neuritic
and amyloid plaques in Alzheimer’s disease (AD) did not
reveal Aβ plaques in our patient; many neuronal cell bod-
ies, however, were Aβ immunopositive in the entorhinal
cortex layers 3 and 4 (Figure 5b). With the α-synuclein
antibody, no abnormal α-synuclein in the form of clas-
sical Lewy bodies was found in the substantia nigra, as
verified by the H&E stain, or as cortical Lewy bodies
(not shown). No displacement of TDP43 from the nu-
cleus to the cytoplasm or neurites was identified in any
brain regions examined (not shown). Ubiquitin and PrPSc
double immunofluorescence staining of the curvilinear
PrPSc deposits in the putamen and the cerebellar den-
tate nucleus did not show ubiquitin positive structures
(not shown).
Western blot analysis of the proteinase K (PK)-resistant
PrP (PrPSc) from our patient showed PrPSc with gel mo-
bility of the unglycosylated PrPSc isoform of ~19 kDa,
matching PrPSc type 2 (Figure 6a). There was prominent
Figure 3 Neuropathological immunohistochemistry of the E200G and a representative E200K case for comparison. (a-g E200G; h E200K)
(a-b) insular cortex, (c) dentate nucleus, (d, i-j) putamen, (e, f) hippocampus, (g) thalamus, (h) E200K-129M thalamus. (a) Finely granular (synaptic)
pattern of PrPSc accumulation occurs in layers V-VI, with a few larger PrPSc deposits (arrow). (b) H & E stain reveals vacuolation mostly in cortical layers
V-VI. (c) A cerebellar dentate nucleus neuron shows granular deposits of PrPSc inside and around the perikarya and processes. (d) Many punctate linear
and curvilinear arrays of PrPSc were located in the putamen. (e) Moderate to severe PrPSc accumulation is shown in the hippocampus, where (f) H & E
stain shows no vacuolation (the same area as E). (g) H & E stain shows severe neuronal loss and reactive astrocytosis with mild vacuolation in the
medial nucleus of thalamus (a representative astrocyte marked with an arrow). (h) H & E stain shows small vacuoles but neither neuronal
loss nor reactive astrocytosis in the medial nucleus of thalamus of an E200K-129M patient (a representative neuron marked with an arrow).
(i) PrPSc (red fluorescence) in the linear and curvilinear arrays contacts dendrites stained for MAP-2 (green fluorescence) along its course. (j)
Some of PrPSc (red fluorescence) in the arrays is co-localized (yellow fluorescence, arrowheads) with synaptophysin (green fluorescence).
Other PrPSc staining, however, is not co-localized, but in close proximity to synaptophysin., suggesting it is near pre-synaptic axonal terminals.
Bars below b and c, 50 μm. Bar below d, 30 μm applying also to a. Bar below e, 100 μm, applying also to f. Bar below g, 50 μm applying also to
h. Bar below i, 20 μm applying also to j. Layers of the cerebral cortex are indicated. “wm” indicates white matter.
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sentation of unglycosylated PrPSc species (Figure 6a).
Comparison to E200K cases evaluated through the NPDPSC
To compare the clinical and pathological phenotype of
our E200G-129V(M) (trans M) case to that of E200K,we selected three E200K-129V(M) cases for whom suf-
ficient clinical data were available from among the six
NPDPSC cases used for histopathological examination.
Table 3 summarizes the clinical and pathological findings
of these NPDPSC E200K-129V(M) cases, ages 37–67.
These three NPDPSC E200K-129V(M) cases all initially
Figure 4 Punctate linear and curvilinear arrays of PrPSc in various brain regions. The PrPSc stain shows the punctate linear and curvilinear
deposits of PrPSc in the putamen, hippocampus CA4, substantia nigra (Substantia Nig.), midbrain tegmentum (Midbrain Teg.) medullary
tegmentum (Medullary Teg.), and cerebellar dentate nucleus (Dentate Nuc.) at low (10x) and high (40x) magnifications. Bar below 10x is 150 μm
and bar below 40x is 50 μm.
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decline, and progressed rapidly over 7–9 months. One
case had myoclonus in the arms and two cases showed
slowing on EEG. All three cases reportedly showed re-
duced striatal diffusion on brain MRI but no definitive
cortical ribboning was reported (although cortical rib-
boning is often missed [16]). Pathological examination
of these three NPDPSC E200K-129V(M) cases showed
classical features of CJD throughout the cerebral cor-
tex, striatum, hippocampus, and cerebellum and type
2 PrPSc. These three cases (as well as the three other
histopathologically-analyzed cases without sufficient
clinical history) also showed mild to moderate, punctate
linear and curvilinear PrPSc deposits in the midbrain and
cerebellar dentate nuclei. In addition, this punctate linear
and curvilinear PrPSc deposition pattern was also observed
in most E200K-129M(V) cases (8 of 9 cases examined), par-
ticularly in the putamen, globus pallidus, midbrain, cerebel-
lar dentate nucleus, and hippocampus (Table 4).
Notably, all three NPDPSC E200K-129V(M) cases showed
marked atrophy of the cerebellum (global in two cases
and focal in one case), which exhibited severe diffuse,
fine synaptic PrPSc deposits (occasional small PrPSc aggre-
gates present but no plaque-like formation), vacuolationand reactive astrocytosis in the cerebellar cortex. Two
NPDPSC E200K-129V(M) cases which did not have clinical
information and were used for histopathological exam,
also showed very similar cerebellar pathology to these three
cases (not shown). One case which was not included in this
clinical and pathological comparison due to insufficient
clinical information available (Table 3, Legend) showed
focal PrPSc deposits with a perpendicular orientation to the
cerebellar pial surface. Table 4 compares pathological
findings of our E200G case and E200K-129V(M) and
E200K-129M(V) (E200K; taken from the literature and
the NPDPSC cases).
For a comparative molecular study of PrPSc, we included
NPDPSC brains from E200K-129V(M), E200K-129M(V),
sCJDMM1 and sCJDVV2. E200K-129V(M) PrPSc co-
migrated with the PrPSc type 2 of E200G-129V(M). A
fragment of ~17 kDa was detected in the cerebellum of
two E200K-129V(M) (one case shown in Figure 6a, line 3),
but not in our patient, nor in E200K-129M(V). PrPSc from
one E200K-129M(V) case, however, migrated about 1 kDa
slower, to ~20 kDa (Figure 6a, lines 9–11) matching PrPSc
type 1, whereas another E200K-129M(V) case showed
type 2 PrPSc (Figure 6a, lines 12–13). To better understand
the spectrum of PrPSc types in E200K CJD, we selected
Table 2 Lesion profiles of the E200G case
Pathology\ Brain regions PrPSc depositiona Vacuolationb Reactive astrocytosisc
Frontal Layers 5, 6 ++/+++ (S/PL/FG) Layer 6 +++ Pattern1: layer 1 +
Layers 2–5 ++ Pattern 2: layers 1–4 ++
Layers 1–4 + (FG) Pattern 3: layers 1–6 +++
Parietal Layers 5, 6 ++ Layers 5–6 ++ Pattern1: layer 6 ++
(S/PL/FG) Layers 2–4 + Pattern 2: layers 2–6 ++
Layers 1–4 + (FG)
Temporal Layers 5, 6 ++/+++ (FG) Lattern 1: Pattern 1: layers 1–5 ++++




Layers 2–4 ++++ (SS)
Occipital Layers 5, 6 + (FG) Layer 6 + Layers 1–6 −/+
Layers 1–4 −/+ (FG)
Cingulate Layers 1–6 +++ (FG) Layers 2–3 ++ Layers 2–6 ++++
Layers 4–5 +++
Layer 6 ++
Insula Layers 5, 6 +++ (FG) Layers 5–6 +++ Layers 1–4 +++
Layers 1–4 ++ (FG) Layers 2–3 ++ Layers 5, 6 −
Caudate +++ (S, FG) +++ +++
Putamen +++ (S, FG) +++ +++
Globus pallidus Ext. +++ (FG) Ext. + Ext.++/+++
Int. ++/+++ (FG) Int. + Int. ++
Thalamusd Rostral: med.+/++ (S), lat. − Rostral: med.++, lat.−/+ Rostral: med.++/+++, lat. +/++
Middle: med. + (S), lat. − Middle: med.++, lat.+ Middle & caudal: med. ++/+++, lat. −/+
Caudal: med. 1+ but focal 2+, lat. - Caudal: med.++/+++, lat. +
Amygdala ++/+++ (FG) +++ ++/+++
Hippocampusd Dentate gyrus, CA4, CA3, and CA2: −/+ CA4, CA3, CA2, and CA1 prox. – CA4, CA3 ++
CA2, CA1 prox. –
CA1: prox. ++, CA1 dist.+++ (FG) CA1 dis. ++ CA1 dis. ++,
Subiculucm: +++ Subiculum: Subiculum ++,
Entorhinal cortex: layers 5, 6 ++/+++ Layer 4 +++ Entorhinal cortex: layers 2–6 ++
Layer 2 +/++
Layers 1–4 −/++ (FG) Entorhinal cortex Transentorhinal cortex: layers 2–6 +++
Transentorhinal cortex: layers 1–6 +++ (FG) : layers 2,4 +++
Transentorhinal cortex
: layers 2–6 +++
Cerebellum Molecular and granular layers −/+ Molecular and granular
Layers – dentate nucleus +
Molecular layer ++/+++
Granular layer +/++
Dentate nucleus +Dentate nucleus +
Midbrain Periaqueductal gray and tegmentum + (FG) Periaqueductal gray ++ Periaqueductal gray +
Tegmentum + Tegmentum ++/+++
Kim et al. Acta Neuropathologica Communications 2013, 1:80 Page 7 of 17
http://www.actaneurocomms.org/content/1/1/80
Table 2 Lesion profiles of the E200G case (Continued)
Substantia nigra ++/+++ (FG) ++ +/++
Medulla Tegmentum ++ (FG) Tegmentum + Tegmentum +
Inf. olive ++/+++ (FG) Inf. olive - Inf. olive +
a PrPSc deposition scored on a 4-level scale: - absent, + mild, ++ moderate, +++ severe; b Vacuolation scored on a 5-level scale - absent, + mild, ++ moderate, +++
moderately severe, ++++/SS very severe/status spongiosis. c Reactive Astrocytosis scored on a 5 -point scale - absent, + mild, ++ moderate, +++ moderately
severe, ++++ very severe. d data shown is from UCSF pathological analysis. NPDPSC analyses were generally in agreement with UCSF analyses except NPDPSC
found +++ PrPSc in medial thalamus and hippocampus. Abbreviations: S Synaptic, PL Plaque-like, FG Finely granular, SS Status spongiosus, ext. Externa,
int. Interna, med. Medial, lat. Lateral, prox. Proximal, dis. Distal, inf. Inferior.
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were available. Among seven E200K-129V(M) cases, 86%
were type 2 (n = 6) and 14% were both types 1 and 2 (n = 1)
and all E200K-129V(V) cases were type 2 (n = 4). Among
the E200K-129M(V) cases, 47% were type 1 (n = 9), 26.5%
each were type 2 (n = 5) and both types 1 and 2 (n = 5).
Among the E200K-129M(M) cases, 91% were type 1
(n = 49) but 9% were both type 1 and 2 (n = 5) (Table 5).
Having found that each group had diverse PrPSc types,
we examined whether codon 129 polymorphism and PrPSc
types affected clinical manifestations (age at disease onset
and disease duration) of E200K CJD (Table 5). We found
that the E200K-129V cohort had the longer disease duration
than the E200K-129M (9 ± 4 vs. 5 ± 4.5 months, p = 0.024).
But among the E200K-129V cohort, there was no difference
in the duration between 129V(M) and 129V(V) cases
(8 ± 1 vs.10 ± 6, p = 0.75). Interestingly, among the E200K-
129M cohort, cases with 129M(V) had the longer duration
than those with 129M(M) (9 ± 7 vs. 4 ± 2 months, p = 0.004).
We also found that among the E200K-129M(V), cases
with PrPSc type 2 had the longer duration than those
with type 1 (16.5 ± 8 vs. 5.5 ± 3 months, p = 0.036). But the
age at disease onset was not affected by either codon 129
polymorphism or PrPSc types in E200K patients of both
haplotypes (E200K-129V vs. E200K-129M, p = 0.21; E200K-
129V(M) vs. E200K-129V(V), p = 0.83; E200K-129M(V) vs.Figure 5 Hyperphosphorylated tau and β-amyloid (Aβ) immunoreacti
neuropil threads and four neuronal cell bodies are found in the entorhinal
cell bodies are Aβ positive in the entorhinal cortex layers 3 and 4. Bar in bE200K-129M(M), p = 0.18; E200K-129M(V) PrPSc type 2 vs.
E200K-129M(V) PrPSc type 1, p = 0.45).
On the other hand, the representations of the di-, mono-
and unglycosylated isoforms of PrPSc in E200K-129V(M)
and -129M(V) were similar to that of our E200G patient,
characterized by the prominent representation of diglycosy-
lated PrPSc and underrepresentation of unglycosylated
PrPSc species (Figure 6a-b); the amounts of the three glyco-
forms (di-, mono-, and unglycosylated PrPSc), expressed as
percent distribution of each form, were 51:38:11 in our
patient, 52:39:9 in E200K-129V, 49:40:11 in E200K-129M-
PrPSc type 1, and 54:38:8 in and E200K-129M-PrPSc type
2 (Figure 6b). As expected, the PrPSc glycoform ratios as-
sociated with our patient and the E200K differed from
those of sCJDMM1 and sCJDVV2 in which the monogly-
cosylated PrPSc was predominant (sCJDMM1: 21:46:33;
sCJDVV2: 35:49:16) (Figure 6b).
Materials and methods
The work in this paper was approved by the UCSF
Committee on Human Research and University Hospitals
Case Medical Center Institutional Review Board. The
proband and her sibling were subjects in a UCSF re-
search study on human prion disease that includes an
extensive standardized clinical evaluation. Autopsy and
sampling of material for histopathological analyses ofvity in the E200G case. (a) Many hyperphosphorylated tau positive
cortex layers 3 and 4. (b) No Aβ plaques are seen but many neuronal
represents 100 μm and applies also to a.
Figure 6 Prion typing. Determination of electrophoretic mobility and PrPSc glycoform ratio in gPrD with E200G and E200K mutations. (a)
Western blot analysis of PrPSc from an E200K-129V patient (lanes 1–3), our E200G case (lanes 4–6), an E200K-129M patient associated with PrPSc
type 1 (lanes 9–11) and an E200K-129M patient associated with PrPSc type 2 (lanes 12–13). The mobility of the unglycosylated PrPSc from E200G
is ~ 19 kDa as that of PrPSc type 2 and matches the corresponding mobility observed in E200K-129V and E200K-129M associated with PrPSc type
2. A fragment of ~17 kDa (indicated by the asterisk) was detected in the cerebellum of the two E200K-129V. PrPSc from sCJDMM1 (lane 7) and
sCJDVV2 (lane 8) subtypes have been loaded as control. Frontal (lanes 1, 4, 7–9 and 12), parietal (lane 5), occipital (lanes 2, 10 and 13) cortices
and cerebellum (lanes 3, 6 and 11) were examined. (b)The amounts of di-, mono- and unglycosylated PrPSc glycoforms expressed as percentage
of the total PrPSc are virtually identical in all cases associated with the E200G and E200K mutations, but they differ from those of sCJDMM1 and
sCJDVV2. Bar graphs are expressed as mean ± SEM of the two cortical regions from cases of E200K-129M (n = 3), E200K-129V (n = 4), and E200G,
and one region from sCJDMM1 (n = 1) and sCJDVV2 (n = 1).
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scribed [18] including the thalamus and cerebellum.
One half of the brain was frozen, the other fixed in for-
malin [19]. Immunohistochemistry on fixed sections
and histoblot on frozen sections were performed as
previously described [20-24]. Histologic sections were
evaluated and assessed for PrPSc deposition with 3F4
antibody (from Dr. Stanley Prusiner), vacuolation with
hematoxylin and eosin staining, reactive astrocytosis
with GFAP staining (polyclonal rabbit, catalog # Z0334,
Dako, Carpinteria, CA), and dendritic staining with MAP-2
antibody (polyclonal rabbit, catalog # AB5622, Millipore,
Billerica, MA), as previously described [18,19,22]. Neuronal
loss was judged by visual assessment as absent, mild,
moderate or severe. The presence of other proteinopathies
was assessed by antibodies for hyperphosphorylated tau
(CP13, from Peter Davies), β-amyloid (mouse anti-β-
amyloid monoclonal Ab (mAb), 4G8, catalog# NE1002,
Millipore), α-synuclein (mouse mAb, catalog# ab27766,Abcam, Cambridge, MA), TDP43 (rabbit polyclonal,
catalog # 10782-2-AP, Proteintech Group, Inc. Chicago, IL),
and ubiquitin (rabbit polyclonal, catalog # Z0458, Dako), as
previously described [25].
PRNP analyses and Western blot for typing of the
proteinase K (PK)-resistant PrPSc were performed by the
National Prion Disease Pathology Surveillance Center
(NPDPSC) (Cleveland, OH) [2]. For a comparative molecu-
lar study of prion typing, frozen brains were collected by
the NPDPSC from genetic prion disease (gPrD) E200K-129
V (n = 4), E200K-129M (n = 3), sCJDMM1 (n = 1) and
sCJDVV2 (n = 1). All E200K cases selected from the
NPDPSC database were heterozygous at codon 129;
Due to the rarity of E200K-129 V cases, all available
cases were used without applying any inclusion/exclusion
criteria. E200K-129M had age of disease onsets similar to
that of our E200G case, with disease durations felt to be
representative of most of the E200K NPDPSC cohort.
For histopathological comparison, immunohistochemistry
Table 3 Clinical features of NPDPSC E200K-129V (trans M) cases*
Patient C Patient E Patient F
Age/gender 37 yo/male 57 yo/female 67 yo/female
Age of onset 37 yo 57 yo 67 yo
Duration of illness 9 months 8 months 7 months
First symptom Gait difficulty Gait difficulty and nonspecific dizzy feeling Veering to the left and worsening gait
Other symptoms and
cognitive tests
Speech difficulty; dysarthria Blurry and double vision at 2–3 months Weak voice,
Hands tremor,
MOCA 19/30 at 4 months Curled hands, clumsy hands Unable to write,
Short term memory decline at 2–3 months
Cognition deterioration MMSE 25/30 (no recall, no copy of design) at 4 months,
MMSE 19/30 (missing points on orientation and recall)
at 4 months
MOCA 10/30 at 4 months
MMSE 27/30 at 5 months (remote recall 0/3)
Myoclonus and other abnormal
neurological findings
Myoclonus + in arms Myoclonus - vertical gaze palsy+ Myoclonus - postural tremor+, bradykinesia +
EEG N/A Intermixed bursts of delta and theta activity at 4 months Right temporal slowing at 4 months
Brain MRI Read normal at 2 months. Reported as only periventricular white matter changes
at 2 month.
Reported as high T2 signal in the cerebellar gray matter
and vermis, cerebellar atrophy at 3 months.
At 3 months, reported as symmetrical T2
and DWI hyperintensity in the caudate,
putamen, and pulvinar
Restricted diffusion in the caudate at 4 months At 4 months, restricted diffusion in the caudate
bilaterally, subtle restriction in the thalamic
pulvinar area, left greater than right, and questionable
high cortical intensity in the mesial frontal and parietal
high convexities on DWI but no corresponding ADC
findings, increased signal in the entire cerebellum on DWI
Other imaging Unremarkable C, T, and L spine MRIs Disc bulging on C-spine MRI Normal pelvic US and breast MRI
CSF profile Clear, colorless, WBC 0, protein 61(15–60), Positive 14-3-3 Clear, colorless, WBC 0, protein 46 (12–60), glucose 84
(40–70)
tau 14746 pg/mL 14-3-3 4.5 ng/mL
glucose 65 (45–75) (nl < 1.5 ng/mL, Mayo clinic)
Positive 14-3-3 CSF paraneoplastic panel: negative (Mayo clinic)
tau 20360 pg/mL
Other labs Serum paraneoplastic panel negative Serum paraneoplastic panel negative
PrPSc type 2 2 2
Family history for CJD Unknown Positive for progressive movement problems and
dementia: 2 family members + for genetic testing
for prion disease





















Table 3 Clinical features of NPDPSC E200K-129V (trans M) cases* (Continued)
Histological and
immunohistochemical findings
1.Vacuolation and reactive astrocytosis Similar to patient C but with less intense PrPSc
immunostaining and no plaque-like PrP Sc
formations.; Global cerebellar atrophy
Similar to patient C but with less intense PrP Sc
immunostaining and no plaque-like PrP Sc formations.;
Focal cerebellar atrophy1) Intense in the cerebral neocortex, basal
ganglia, hippocampus, and cerebellum
2) Mild to moderate vacuolation in the thalamus
3) Vacuolation more severe in the basal
ganglia than the cerebral cortex and thalamus
2. PrPSc deposits
1) Diffuse and plaque like deposits in the
cerebral cortex
2) Presence of intraneuronal PrPSc deposit
3) Moderate PrPSc deposits in the
hippocampus and entorhinal cortex
4) Severe diffuse PrPSc deposits in the cerebellar
molecular and granular layers, occasional small
PrPSc aggregates in the cerebellar granular layer;
Marked global atrophy of the cerebellum
5) Linear and curvilinear PrPSc deposits in the
midbrain and cerebellar dentate nucleus
* There were six E200K-129 V NPDPSC cases (A-F). No clinical information was available for Cases A and B. Case D, an 85 yo woman with dementia and known family history of E200K presenting with confusion but no
other known clinical history, was not included in the table due to limited clinical information. Her MRI reportedly showed atrophy, chronic, microvascular ischemic change. Pathology revealed senile plaques of
Alzheimer’s disease and mild vacuolation throughout the neocortex. Vacuolation was mild in the hippocampus, moderate in the entorhinal cortex and putamen. The cerebellum showed vacuolation without atrophy
and also had focal PrPSc deposit with a perpendicular orientation to the cerebellar pial surface. Immunostaining was similar to that of Patient C but no plaque-like PrP formations were observed overall. PrPSc was type





















Table 4 Summary of histopathological and molecular comparison between the E200G and E200K cases
E200G-129V (M) E200K-129V(M) [17] E200K-129M(V) [1,8,14]
Pathologya\ Brain regions A B C D A B C D A B C D
Cortex +++ +++ +++ ++ /+++ ++/+++c +++b n/a +++b +++d +/++e +++d +++d
+/++e +/++e +/++e
Striatum +++ +++ +++ ++ /+++ ++/+++c +++b n/a +++b ++d ++e ++d, e ++d, e
++/+++e
Hippocampi ++/+++ - - - +b ++/+++b n/a +++b ++e +e +e +e
++/+++b
Thalamus +++ +/++ +++ +++ ++/+++c +b -b -b ++/+++e ++e ++e ++e
+b -b -b
Cerebellum + + +/++ ++ ++/+++b +++b n/a +++b ++d +e ++d ++d
+++c ++e +e +e
Vacuole size, mean 14. 9 11.9 11.8
(range μm) (4–108)b (4–72)b (4–69)b




Finely granular synaptic +++e, f
Plaque-like + Plaque ++/+++b, c Plaque-like ++/+++e, +f
Intra-neuronal + Intra-neuronal + b Intra-neuronal ++/+++e
Regions with linear and
curvilinear arrays of PrPSc
Striatum, hippocampi Put, GP(20%) Put, GP
SN, PAG (12.5%)
SN (67%) CA4 of hippo (37.5%)





PrPSc type 2 2c 1 (47%),
2(86%), 1 + 2(14%)b 2 (26.5%),
1 + 2 (26.5%)b
Abbreviations and Definitions: aA PrPSc deposit, B Vacuolation, C Neuronal Loss, D Reactive Astrocytosis, SN Substantia nigra, MT Midbrain tegmentum, PAG Periaqueductal gray matter, MION Medullary inferior olivary
nucleus, CDN Cerebellar dentate nucleus, Put Putamen, GP Globus pallidus, - absent, + mild, ++ moderate, +++ severe, b NPDPSC analysis in this study, c from reference [17] (n = 1), d from reference [1], e from reference


























n Type 1 PrPSc Type 2 PrPSc Type 1 & 2 PrPSc All PrPSc Types
% Disease duration % Disease duration % types Disease duration Disease duration Age at onset
129 type 1 (mean± SD; range) type 2 (months, mean ± SD; range) 1 and 2 (months, mean ± SD; range) (months, mean ± SD; range) (years mean± SD; range)
E200K-129V
M 7 0 - 86% 8 ± 1 14% 10 8 ± 1 56 ± 12
(n = 6) (7–9) (n = 1) (7–10) (37–67)
V 4 0 - 100% 10 ± 6 0 - 10 ± 6 54 ± 12
(n = 4) (2–17) (2–17) (37–66)
All 11 0 - 91% 9 ± 4 8% 10 9 ± 4 a 55 ± 11
(10) (2–17) (n = 1) (2–17) (37–67)
E200K-129M
M 54 91% 4 ± 2 0 - 9% 4 ± 2 4 ± 2 b 59 ± 11
(n = 49) (1–12) (n = 5) (2–7) (1–12) (40–85)
V 19 47% 5.5 ± 3 c 26.5% 16.5 ± 8 c 26.5% 7 ± 4 9 ± 7 b 63 ± 7
(n = 9) (3–10) (n = 5) (6.5-29) (n = 5) (2–11) (2–29) (53–76)
All 73 79% 4 ± 2 7% 16.5 ± 8 14% 5 ± 3 5 ± 4.5 a 60 ± 10
(n = 58) (1–12) (n = 5) (6.5-29) (n = 10) (2–11) (1–29) (40–85)
Abbreviations and Definitions: n Number of cases, Bold denotes subgroups with significant differences. a E200K-129V had longer duration than E200K-129M (p = 0.029); b E200K-129M(V) lived longer than E200K-129MM
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E200K-129M (n = 9) that had disease durations with a
range of 7 to 10 and 3 to 29 months, respectively. All
E200K-129V cases were analyzed for IHC. The nine
E200K-129M(V) (trans V) cases were chosen for IHC
to be representative of the E200K-129M population.
The entire NPDPSC E200K-129M(V) cohort has a
mean disease duration of 9 ± 7 (SD) months. One long
duration E200K-129M(V) case, with a disease duration
of 29 months, was included because it was close in dur-
ation to our E200G case; thus the mean disease duration
of these nine E200K-129M(V) cases was 12 ± 7 (SD)
months (10 ± 4 [SD] months without the long-duration
29 month case).
Preparation of the brain homogenates and Western
blot analysis
Brain homogenates (BH) (20% w/v) were prepared in 1X
Dulbecco’s phosphate buffer saline (DPBS), pH 7.4, then
mixed with an equal volume of 2X lysis buffer contain-
ing 100 mM Tris (100 mM NaCl, 0.5% Nonidet P-40,
0.5% sodium deoxycholate, 10 mM EDTA, 100 mM
Tris–HCl, pH 8.0). The BH was centrifuged at 1000 g
for 5 minutes and the collected supernatant (S1) was
digested with 10 U/ml proteinase K (PK) (1 U/ml equal
to 20 μg/ml PK) at 37°C for 1 hour. Samples were loaded
onto a 15% Tris–HCl polyacrylamide precast gel, trans-
ferred, then incubated with the primary prion protein
antibody 3 F4 (1:40,000) for 2 hours. The prion protein
was visualized by the Odyssey infrared imaging system.
Densitometric analysis was performed with Odyssey appli-
cation software V3.0 (LI-COR Biosciences).
Vacuole size determination and statistical analysis
The diameter (μm) of the vacuoles from the cerebral
cortex of E200G, E200K-129M (n = 3), and E200K-129V
(n = 3) was measured by the software Image-Pro Plus
(Media Cybernetics, Inc.). Statistical analysis was per-
formed with GraphPad Prism 6.0 using the nonparametric
Mann Whitney test with Bonferroni correction of the level
of significance value (α) which is equal to 0.016. For com-
parisons of disease duration and age of onset of various
E200K haplotypes, Student t test with Welch's correction
was used.
Conclusions
To our knowledge this is the first report of an E200G
mutation associated with a CJD phenotype. Several reasons
strongly suggest that this mutation is pathogenic. Firstly, it
is in the same codon as the most common PRNP mutation,
E200K causing genetic CJD. Secondly, the change from
a glutamate to glycine is non-conservative, substituting
a large, acidic amino acid with a side-chain, with a much
smaller, non-acidic amino acid without a side-chain thatmight affect the propensity for misfolding of PrP. Thirdly,
some of the uncommon pathological features and PrPSc gly-
cosylation pattern argue against this case being sCJD; prom-
inent involvement of the deeper cortical layers observed in
our patient is rare in most sCJD, except sCJD VV2. Al-
though our patient was MV2, there were no amyloid kuru-
type plaques, which is in contrast to sCJD MV2 in which
amyloid kuru-type plaques are typically present [22]. Both of
these findings (involvement of the deeper cortical layers and
and the absence of amyloid kuru-type plaques), however,
are frequently observed in E200K genetic prion disease
(gPrD) [26]. Our patient had type 2 PrPSc but with the
underrepresentation of the unglycosylated form (Figure 4),
another characteristic of genetic prion disease, including
CJD E200K and FFI, but not sCJD [27-29]. Lastly, although
the father was reported to have an “alcoholic dementia”
with a very rapid decline, we suspect that he died of gPrD.
Not uncommonly in our gPrD families, we find that prior
to a PRNP mutation being identified, some family members
with gait ataxia and dementia were assumed to have had al-
coholism causing cognitive impairment and gait problems.
To compare clinical and pathological phenotypes of
our patient with those of E200K, we conducted exten-
sive literature review as well as new pathological and
molecular analyses on the E200K cases selected from the
NPDPSC database. One might expect for E200G-129V,
type 2 PrPSc to have similarities to the very rare E200K-
129V, type 2 PrPSc. We are aware of only two previously
published cases of the E200K-129V; one V(M), like our
patient, and the other V(V); both also had type 2 PrPSc
that also were primarily diglycosylated [17,29]. The codon
129V(V) E200K patient was a 66-year-old woman with
a 15.5 month course, beginning with one year of ver-
tigo and ending after 3.5 months of rapidly progressive
dementia. Similar to our patient she had no myoclo-
nus; her EEG, however, showed focal triphasic spikes.
MRI reportedly only showed ventricular enlargement,
and probably did not include FLAIR or DWI [29]. The
E200K-129V(M) case was a 67-year-old woman with a
six-month course, beginning with gait ataxia and then
rapidly progressive dementia at 4 months, but died of a
pulmonary embolism. She had focal myoclonus in her
later stages, but no PSWCs on EEG and MRI findings
were not reported [17]. Our patient’s age of onset was
a decade younger (57 years) and had a longer duration
(30 months), than the E200K-129V cases, but similarly
had early gait disturbance and late dementia [17,29].
Despite our patient’s most prominent, early and debilitating
symptom of ataxia, her cerebellum was very mildly affected
pathologically (Table 2). In contrast, PrPSc accumulation
was noted in the cerebellum of both published E200K-
129V cases; the E200K-129V(V) patient with predominant
plaque-like PrP deposits [29] and the E200K-129V(M)
patient with focal PrPSc deposits with a perpendicular
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layer [17].
Compared with the NPDPSC E200K-129V(M) cases
(mean age at onset 56 ± 12 years [range 37–67 years], mean
duration 8 ± 1 months [range 7–9 months], Table 5),
however, our E200G patient had a similar age at onset,
but a much longer disease duration. Common features
between the E200G case and three well-characterized
cases of NPDPSC E200K-129V(M) (Table 3) are initial gait
difficulty followed by memory decline, striatal involvement
on brain MRI, slowing on EEG, elevated CSF tau level,
and type 2 PrPSc. But, cortical ribboning which was mild
in our E200G patient, was not observed in the NPDPSC
E200K-129V(M) and myoclonus was reported in one
NPDPSC E200K-129V(M) case (Table 3). In our experi-
ence, however, in most E200K cases which are reported
to not have cortical ribboning on DWI/ADC MRI, we
identify cortical ribboning. A majority of MRIs in CJD,
unfortunately, are misread [16,30]. Pathologically, cerebellar
involvement was much more severe in the NPDPSC
E200K-129V(M) cases than our case. Only one of the six
NPDPSC E200K-129V(M) cases examined histopatho-
logically (Table 3, Legend) showed the similar focal PrPSc
deposits perpendicular to the cerebellar pial surface to
the published E200K-V(M) patient [17]. The other five
NPDPSC E200K-129V(M) cases (Table 3 and not shown)
did not show either plaque-like PrPSc deposits or focal
PrPSc deposits with a perpendicular orientation in the
cerebellar cortex. We found marked atrophy in their
cerebella, however, accompanied by severe diffuse PrPSc
deposits and severe vacuolation and reactive astrocytosis,
which are in great contrast to the mild cerebellar involve-
ment of our E200G patient (Tables 2 and 3). In addition,
we detected another fragment of ~17 kDa of PrPSc in the
cerebellum of the two NPDPSC E200K-129V(M) cases
with Western blotting, which was not observed in our
patient (Figure 6). Whether the cerebellar presence of the
17 kDa fragment is a distinctive feature of E200K-129V(M)
remains to be determined. There are clearly overlapping as
well as distinguishing features between our case and the
E200K-129V(M) gPrD patients.
Although our patient was cis 129V, she had many fea-
tures in common with the most prevalent form of E200K,
with 129M cis (E200K-129M). The age at onset (57 years)
in our case is consistent with those of E200K-129M, with a
published mean age at onset 58 years (range 33–84 years)
[5,8,10] and those of NPDPSC with 60 ± 10 years (range
40–85 years) (Table 5). Our patient’s duration of illness
(30 months), however, is longer than the published mean
duration of E200K (6; range 2–41 months) and those of
NPDPSC (5 ± 4.5; range 1–29 months) (Table 5) but within
the published range [5,8,10]. Brain MRI findings of the
predominant striatal involvement and mild cortical ribbon-
ing observed in our patient (Figure 2) are also common inE200K-129M [31,32]. Pathologically, the pattern of PrPSc
deposits was diverse in our patient (synaptic, coarse
granular, and plaque-like deposits) overlapping with those
in Slovakian E200K-129M (synaptic pattern mainly in
129MM and granular or plaque-like deposits in 129MV)
cases [8]. Involvement of deep cortical layer and no amyloid
kuru-type plaques of PrPSc were both present in our patient
and also are in E200K-129M (Figure 3) [26].
Our case also had several differences from those typic-
ally found in E200K-129M. Our patient initially pre-
sented with gait ataxia followed by dementia, whereas
dementia typically occurs first in E200K-129M [5,8,10].
Our patient did not develop myoclous or EEG PSWCs,
which are very common in published E200K-129M cases
(myoclonus in 73% and PSWCs in 75%) [33,34]. A charac-
teristic stripe-like pattern with a perpendicular orientation
of PrPSc deposits in the cerebellum noted in published
E200K-129M [14,26,35] cases was not observed in our
case. In addition, our patient had type 2 PrPSc, whereas
E200K-129M cases have type 1, 2 or mixture of both
types [14,29,36]. Other differences between our patient
and E200K cases examined were the larger vacuole sizes
(the mean diameter of the vacuoles from E200G signifi-
cantly larger than those of the NPDPSC E200K-129M and
E200K-129V), no vacuolation in the hippocampus (despite
abundant PrPSc staining), and the severe involvement of the
thalamus (severe atrophy, PrPSc deposits, neuronal loss,
and reactive astrocytosis, and mild vacuolation) (Figure 3).
Vacuolation in the hippocampal pyramidal cell layer was
observed in the NPDPSC E200K-129M (6 cases out of 7
cases examined) and -129V cases (all 6 cases examined).
The thalamic changes noted in our case have been reported
only in one case of E200K-129M [37] and commonly seen
in sporadic and familial fatal insomnia [38,39].
In one previous study, Hτ positive neuritis (93.3%), par-
enchymal Aβ (53.8% but only occasional neuritic plaques)
and Lewy type α-synuclein pathology (15.4%) were reported
in E200K (all codon 129 polymorphisms, except no V(M)
were represented) [14]. We found Hτ-positive neuronal cell
bodies and neuropil threads in the entorhinal cortex of our
patient (Figure 5). This distribution of Hτ was found to be
characteristic of great majority of sCJD and familial CJD
(fCJD) cases analyzed at our center (DeArmond, Tousseyn,
Bajsarowicz, et al., in preparation). It has been reported
that among non-demented subjects 20–50 years of age,
11% had limited number of Hτ’s in the entorhinal cortex
and trans entorhinal cortex [40]. No Aβ plaques were
found in any regions of our patient, however (Figure 5).
This is consistent with our unpublished findings that
only 2 of 14 cases of fCJD had AD neuropathology
(DeArmond et al., in preparation). It is also consistent
with the age of death of our patient (59 years), as CJD-AD
cases are found to occur almost 10 years later (DeArmond
et al., in preparation).
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codon 129 and PrPSc type 2 had longer disease duration
(Table 5). Considering the longer duration of our patient
with E200G-129V(M), PrPSc type 2 than that of E200K-
129V(M), PrPSc type 2 cases, we suspected that this novel
mutation might contribute to the prolonged disease course.
One of the most unusual findings in our case was the
abundant curvilinear arrays of PrPSc in various brain
regions (Figures 3 and 4). To our knowledge there is
only one reported CJD case (unclear if genetic or sporadic)
with a similar pattern of PrPSc deposits [41]. We also
observed this staining, however, in all NPDPSC E200K-
129V(M) and most E200K-129M(V) cases examined histo-
pathologically in this study (Table 4).
The subcellular localization of the PrPSc deposits to
synapses and presynaptic axonal terminals might be re-
lated to transsynaptic spread of PrPSc. It remains unknown
whether PrPSc spreads along defined neuroanatomical
pathways in human prion disease, which is the case in
scrapie-injected mouse [42,43] and hamster models
[44,45]. Notably, the subcortical gray matter and brain
stem enriched in the curvilinear arrays of the synaptic
PrPSc in our patient are known to be preferentially vul-
nerable regions in progressive supranuclear palsy (PSP)
[46]. This is interesting as it is now realized that patho-
logical tau aggregates might propagate by a prion-like
mechanism [47-49]. A recent functional MRI (fMRI) study
in PSP showed the connectivity disruption of the same
dorsal midbrain tegmentum-anchored intrinsic connectivity
network (ICN) (brain stem, cerebellum, striatum and cortex)
[46] as was affected pathologically in our case. The overlap
of the affected brain regions and some PSP-like clinical
features (gait difficulty, saccadic pursuit, slowed velocity
of horizontal saccades, and parkinsonism) in our patient
suggested the possibility of PrPSc spreads through this
PSP-related ICN.
As this was a single case, the spectrum of clinicopatholog-
ical presentation of this novel mutation has yet to be deter-
mined. This case supports, however, the loss of glutamate at
codon 200, and not its replacement with lysine, as the cause
of PrP misfolding. As has been done with E200K [50], a
mouse model of E200G might help further show the
pathogenicity of this novel mutation. The penetrance
of this E200G mutation has yet to be determined. We
suspect that conformational changes of PrPSc caused by
the E200G mutation and the rare codon 129 cis valine
polymorphism might contribute to the distinct clinical
and pathological findings of our patient in contrast to the
E200K-129M and E200K-129V subjects.
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